Longitudinal change in basal ganglia volume in patients with Huntington's disease

Article abstract-Cross-sectional MRI studies demonstrating an association between caudate atrophy and symptom severity and duration of symptoms in patients with Huntington's disease (HD) have been assumed to reflect longitudinal changes in basal ganglia, but such neuropathologic progression has never been directly demonstrated. Subjects in the current study were 23 HD patients at various stages of the disorder who had two MRI images at least 10 months apart (mean interimage interval = 20.8 months). We measured volumes of caudate, putamen, and globus pallidus blind to the order of the images. For each structure, we calculated a change score by subtracting the volume obtained on the follow-up imaging from that obtained on the initial imaging. Results indicated significant decreases over time in caudate, putamen, and total basal ganglia volume. Age at onset and length of trinucleotide repeat correlated significantly with amount of volume change in caudate and total basal ganglia, even after controlling for length of interimage interval, duration of disease, and measures of symptom severity. Amount of change in basal ganglia structures was not significantly correlated with neurologic symptom severity at the time of the initial imaging or duration of symptoms. This is the first longitudinal MRI study to document progressive basal ganglia atrophy in HD, and suggests that quantitative neuroimaging with serial MRI may be useful in monitoring effectiveness of potential treatments. In addition, demonstration of greater rate of basal ganglia atrophy in patients with earlier symptom onset suggests that treatment effects may be more quickly observed in this subgroup of patients than in the general HD population. NEUROLOGY 1997;48: 394-399

[1]  S. Folstein,et al.  A controlled trial of idebenone in Huntington's disease , 1996, Movement disorders : official journal of the Movement Disorder Society.

[2]  J. Brandt,et al.  Trinucleotide repeat length and clinical progression in Huntington's disease , 1996, Neurology.

[3]  O. Suchowersky,et al.  Relationship between trinucleotide repeats and neuropathological changes in Huntington's disease. , 1996, Annals of neurology.

[4]  I. Shoulson,et al.  A prospective evaluation of cognitive decline in early Huntington's disease , 1995, Neurology.

[5]  K. Kieburtz,et al.  Functional decline in Huntington's disease , 1995, Movement disorders : official journal of the Movement Disorder Society.

[6]  R. Nemni,et al.  Evidence of peripheral axonal neuropathy in primary restless legs syndrome , 1995, Movement disorders : official journal of the Movement Disorder Society.

[7]  R. Rosenberg.  Autosomal dominant cerebellar phenotypes , 1990, Neurology.

[8]  M. MacDonald,et al.  Trinucleotide repeat length and progression of illness in Huntington's disease. , 1994, Journal of medical genetics.

[9]  Osamu Onodera,et al.  Trinucleotide repeat length and rate of progression of Huntington's disease , 1994, Annals of neurology.

[10]  E. Benarroch,et al.  Neuropeptides in the sympathetic system: Presence, plasticity, modulation, and implications , 1994, Annals of neurology.

[11]  J. Brandt,et al.  Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at‐risk persons , 1994, Neurology.

[12]  C A Ross,et al.  Correlation between the onset age of Huntington's disease and length of the trinucleotide repeat in IT-15. , 1993, Human molecular genetics.

[13]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[14]  S. Folstein,et al.  Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington's disease , 1992, Annals of neurology.

[15]  G Pearlson,et al.  Bicaudate ratio as a measure of caudate volume on MR images. , 1991, AJNR. American journal of neuroradiology.

[16]  D. Sax,et al.  Factors associated with slow progression in Huntington's disease. , 1991, Archives of neurology.

[17]  P. Schmalbrock,et al.  High-resolution 3DFT MR imaging of the endolymphatic duct and soft tissues of the otic capsule. , 1991, AJNR. American journal of neuroradiology.

[18]  J. Kurtzke,et al.  CT brainstem abnormalities in the differential diagnosis of Huntington's disease. , 1990, Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society.

[19]  I. Heuser,et al.  Rationale for continuous dopaminomimetic therapy of Parkinson's disease. , 1989, Neurology.

[20]  G D Pearlson,et al.  Brain atrophy in Huntington's disease. A CT-scan study. , 1989, Neuroradiology.

[21]  J. Vonsattel,et al.  Morphometric Demonstration of Atrophic Changes in the Cerebral Cortex, White Matter, and Neostriatum in Huntington's Disease , 1988, Journal of neuropathology and experimental neurology.

[22]  J. B. Martin,et al.  Clinical and neuropathologic assessment of severity in Huntington's disease , 1988, Neurology.

[23]  M. Mendez,et al.  Cortical auditory disorders: clinical and psychoacoustic features. , 1988, Journal of neurology, neurosurgery, and psychiatry.

[24]  N. Reynolds.  The diagnosis of Huntington's disease , 1987, Neurology.

[25]  R. L. Rogers,et al.  Decreased cerebral blood flow precedes multi‐infarct dementia, but follows senile dementia of Alzheimer type , 1986, Neurology.

[26]  Roberta F. White,et al.  Late onset of Huntington's disease. , 1985, Journal of neurology, neurosurgery, and psychiatry.

[27]  R J Leigh,et al.  The measurement of abnormal movement: methods developed for Huntington's disease. , 1983, Neurobehavioral toxicology and teratology.

[28]  C. Markham,et al.  Cerebral metabolism and atrophy in huntington's disease determined by 18FDG and computed tomographic scan , 1982, Annals of neurology.

[29]  R. Currier,et al.  Progression rate and age at onset are related in autosomal dominant neurologic diseases , 1982, Neurology.

[30]  L. Kuhns.  COMPUTED AXIAL TOMOGRAPHY IN HUNTINGTON'S DISEASE AND PERSONS AT‐RISK FOR HUNTINGTON'S DISEASE , 1980 .

[31]  J. Hallenbeck,et al.  Prevention of postischemic impairment of microvascular perfusion , 1977, Neurology.